Problems in laboratory monitoring of heparin dosage (Q34106860)

31 July 2017

1 reference

title

Problems in laboratory monitoring of heparin dosage (English)

1 reference

31 July 2017

1 reference

Kitchen S

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

British Journal of Haematology

31 July 2017

published in

1 reference

31 July 2017

volume

111

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

397-406

1 reference

Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Anticoagulants in venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

THE CLINICAL USAGE OF HEPARIN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Activated Partial Thromboplastin Time and Minor Coagulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Monitoring of heparin therapy: should heparin assays also reflect the patient's antithrombin concentration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Low molecular weight heparin treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Structure of the antithrombin-binding site in heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Heparin-induced decrease in circulating antithrombin-III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Assay for plasma heparin using a synthetic peptide substrate for thrombin: introduction of the fluorophore aminoisophthalic acid, dimethyl ester

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Correlation between structure and function of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

Heparin in Acute Coronary Disease — Requiem for a Heavyweight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02308.X

10.1046/J.1365-2141.2000.02308.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference